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Objectives The purpose of this study was to compare the incidence of new-onset diabetes (NOD) with cardiovascular (CV)
event reduction at different levels of NOD risk.
Background Statins reduce the number of CV events but increase the incidence of NOD. We previously reported that 4 fac-
tors independently predicted NOD: fasting blood glucose 100 mg/dl, fasting triglycerides 150 mg/dl, body
mass index 30 kg/m2, and history of hypertension.
Methods We compared NOD incidence with CV event reduction among 15,056 patients with coronary disease but without
diabetes at baseline in the TNT (Treating to New Targets) (n  7,595) and IDEAL (Incremental Decrease in End-
points Through Aggressive Lipid Lowering) (n  7,461) trials. CV events included coronary heart disease death,
myocardial infarction, stroke, and resuscitated cardiac arrest.
Results Among 8,825 patients with 0 to 1 of the aforementioned NOD risk factors at baseline, NOD developed in 142 of
4,407 patients in the atorvastatin 80 mg group and in 148 of 4,418 in the atorvastatin 10 mg and simvastatin
20 to 40 mg groups (3.22% vs. 3.35%; hazard ratio [HR]: 0.97; 95% confidence intervals [CI]: 0.77 to 1.22).
Among the remaining 6,231 patients with 2 to 4 NOD risk factors, NOD developed in 448 of 3,128 in the atorva-
statin 80 mg group and in 368 of 3,103 in the lower-dose groups (14.3% vs. 11.9%; HR: 1.24; 95% CI: 1.08 to
1.42; p  0.0027). The number of CV events was significantly reduced with atorvastatin 80 mg in both NOD risk
groups.
Conclusions Compared with lower-dose statin therapy, atorvastatin 80 mg/day did not increase the incidence of NOD in pa-
tients with 0 to 1 NOD risk factors but did, by 24%, among patients with 2 to 4 NOD risk factors. The number of
CV events was significantly reduced with atorvastatin 80 mg in both NOD risk groups. (J Am Coll Cardiol 2013;
61:148–52) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.042Statin therapy reduces the risk of coronary and cerebrovas-
cular events across a broad spectrum of patients (1), and
more intensive treatment provides substantial additional
event reduction (2). However, meta-analyses have shown
that statin therapy is associated with a 9% increase in the
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January 15, 2013:148–52 Cardiac Risk Versus Diabetes With Atorvastatinwere found to be similar across 3 atorvastatin trials (5) and
are similar to the predictors of incident diabetes not related
to statins (6–8).
Despite these considerations, the risk of NOD versus
cardiovascular (CV) event reduction has not been evaluated
at different levels of diabetes risk. The purpose of this study
was to examine, according to baseline risk factors for
diabetes, the incidence of NOD and CV events within 2
large secondary prevention trials with atorvastatin.
Methods
The study design and main findings of the TNT (Treating
to New Targets) and IDEAL (Incremental Decrease in
Endpoints Through Aggressive Lipid Lowering) trials have
been published (9–11). In the TNT study, patients ranged
in age from 35 to 75 years, had documented stable coronary
disease, and had an off-therapy low-density lipoprotein–
cholesterol between 3.4 and 6.5 mmol/l (130 to 250 mg/dl),
decreasing to 3.4 mmol/l (130 mg/dl) after an 8-week
run-in period on atorvastatin 10 mg/day. A total of 10,001
patients were randomized to atorvastatin 10 or 80 mg per
day and followed for a median of 4.9 years. In the IDEAL
study, patients were 80 years of age, had experienced a
definite myocardial infarction (MI), and qualified for statin
therapy according to their national guidelines at the time of
enrollment. A total of 8,888 patients were randomized to
simvastatin 20 to 40 mg per day or atorvastatin 80 mg per
day and followed for a median of 4.8 years.
FBG was measured at each 6-month visit in both TNT
and IDEAL trials. NOD was defined prospectively as at
least 2 post-baseline FBG measurements 7.0 mmol/l (126
mg/dl) and at least 1 post-baseline glucose 2 mmol/l (36
mg/dl) above baseline (12). We also included patients for
whom NOD was identified through adverse event report-
ing. The primary endpoint of the TNT study was a
composite of coronary heart disease (CHD) death, nonfatal
MI, resuscitated cardiac arrest, and fatal or nonfatal stroke;
for the IDEAL trial, the endpoint was a composite of the
first 3 of those for TNT (not including stroke). Each of
these 4 endpoint events are reported in this analysis; total
events as well as patients with events were counted because
many patients had multiple events contributing to the
burden of disease (13).
In the TNT trial, 1,771 patients were excluded because
they were known to have diabetes at baseline or had a
baseline FBG 7.0 mmol/l; an additional 635 were ex-
cluded because 2 post-baseline measurements were avail-
able (n  632) or because the baseline FBG measurement
was missing (n  3). Thus, of the original TNT cohort of
10,001 patients, 7,595 were included in this analysis. In
IDEAL, 1,427 patients were excluded for known diabetes
or a baseline FBG 7.0 mmol/l, leaving 7,461 of the
original 8,888 patients available for this analysis.
Statistical analyses. Comparisons of baseline characteris-
tics between patient groups were based on a 2-sample t test sor continuous variables and
isher’s exact test for categorical
ariables. Variables that were not
ormally distributed, specifically
hite blood cell count and tri-
lyceride levels, were log trans-
ormed. The hazard ratios (HRs)
nd 95% confidence intervals
CIs) for the comparisons of the
evelopment of NOD between
atient groups were calculated on
he basis of Cox proportional hazard analysis. The models
ontained study (TNT or IDEAL) and treatment group.
imilar analyses were used for major CV events.
esults
he baseline characteristics of patients with and without NOD
uring the TNT and IDEAL trials are listed in Table 1.
atients who developed diabetes had higher FBG, triglyc-
ride levels, body mass index, and systolic and diastolic
lood pressure and lower high-density lipoprotein–
holesterol levels at baseline.
The 4 previously defined risk factors for NOD in the
NT and IDEAL cohorts were FBG 100 mg/dl, history
f hypertension, body mass index 30 kg/m2, and fasting
triglycerides 150 mg/dl (5). Figure 1 displays the risk of
OD (top) and the risk of a major CV endpoint (bottom)
or patients with 0, 1, 2, 3, and 4 of the risk factors for
OD. As the number of risk factors for NOD increased,
he CV event rate increased, from 8.5% to 10.1% in the
torvastatin 80 mg group and from 9.0% to 15.0% in the
ower-dose group.
atients at low risk for diabetes. A total of 8,825 patients
ad 0 to 1 of these risk factors at baseline, 4,081 from TNT
nd 4,744 from IDEAL, comprising 53.7% of the TNT and
3.6% of the IDEAL cohorts. NOD developed during
ollow-up in 142 of 4,407 (3.22%) of these patients ran-
omized to atorvastatin 80 mg/day and in 148 of 4,418
3.35%) randomized to atorvastatin 10 mg/day or simvasta-
in (HR: 0.97; 95% CI: 0.77 to 1.22). Among these patients
t low risk for diabetes, 375 of 4,407 patients had at least 1
V endpoint event in the atorvastatin 80 mg group and 433
f 4,418 patients had at least 1 event in the atorvastatin 10
g and simvastatin groups (8.51% vs. 9.80%; HR: 0.87;
5% CI: 0.755 to 0.995; p  0.042).
atients at high risk for diabetes. A total of 6,231 patients
ad 2 to 4 risk factors for diabetes at baseline, 3,514 from
NT and 2,717 from IDEAL, comprising 46.2% of the
NT and 36.4% of the IDEAL cohorts. NOD developed
uring follow-up in 448 of 3,128 (14.32%) of these patients
n the atorvastatin 80 mg group and in 368 of 3,103
11.86%) patients in the lower-dose groups (HR: 1.24; 95%
I: 1.08 to 1.42; p  0.0027). The test for interaction
etween treatment and risk factor group was not statistically
Abbreviations
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CHD  coronary heart
disease
CV  cardiovascular
FBG  fasting blood
glucose
MI  myocardial infarction
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Cardiac Risk Versus Diabetes With Atorvastatin January 15, 2013:148–52for NOD, 315 of 3,128 patients in the atorvastatin 80 mg
group and 373 of 3,103 in the lower-dose group had at least
1 CV endpoint event (10.07% vs. 12.02%; HR: 0.82; 95%
CI: 0.71 to 0.96; p 0.011). The HRs for diabetes and CV
vents in the high- and lower-dose treatment groups ac-
ording to diabetes risk category are shown in Figure 1.




Age, yrs 60.2 8.7
Male 910 (82.3)
Current smoker 194 (17.5)
Hypertension 587 (53.1)
Fasting blood glucose, mg/dl 107.9 10.9
Body mass index, kg/m2 30.0 4.7
White blood cell count,  103/mm3 6.56 1.66
Systolic blood pressure, mm Hg 135.0 18.4
Diastolic blood pressure, mm Hg 80.5 9.8
Total cholesterol, mg/dl 184.9 31.8
LDL-cholesterol, mg/dl 106.6 27.1
HDL-cholesterol, mg/dl 44.3 10.7
Total cholesterol/HDL-cholesterol ratio 4.39 1.30
Triglycerides, mg/dl 155.8 81.3
Use of statin during screening 764 (69.1)
Beta-blockers before or at baseline 747 (67.5)
Treatment  atorvastatin 80 mg 590 (53.4)
Values are mean SD or n (%). Geometric mean and SD are presente
Student t test for continuous variables and Fisher’s exact test for cate
HDL  high-density lipoprotein; LDL  low-density lipoprotein.
Figure 1 Risk of Developing NOD (top) and CV Events (bottom
The new-onset diabetes (NOD) risk factors are fasting blood glucose 100 mg/dl, fas
Atorva  atorvastatin; CI  confidence intervals; CV  cardiovascular; HR  hazard rultiple endpoint events. A total of 690 of 7,535 patients
9.16%) in the high-dose group and 806 of 7,521 in the
ower-dose group (10.72%) experienced at least 1 primary
ndpoint during follow-up (HR: 0.85; 95% CI: 0.77 to
.94; p  0.015). However, the 690 patients with events in
he high-dose group experienced a total of 874 endpoint
tEAL Trialsh and Without




(N  15,056) p Value
61.1 9.23 61.1 9.2 0.001
11,420 (81.9) 12,330 (81.9) 0.776
2,422 (17.4) 2,616 (17.4) 0.869
5,510 (39.5) 6,097 (40.5) 0.0001
97.0 10.0 97.8 10.4 0.0001
27.3 3.9 27.5 4.0 0.0001
6.27 1.73 6.29 1.72 0.0001
132.7 18.5 132.9 18.5 0.0001
79.1 9.8 79.2 9.8 0.0001
185.6 34.2 185.5 34.1 0.514
110.0 30.1 109.7 29.9 0.0001
47.5 11.6 47.3 11.6 0.0001
4.10 1.20 4.12 1.21 0.0001
129.6 62.9 131.4 64.6 0.0001
9,627 (69.0) 10,391 (69.0) 0.973
8,926 (64.0) 9,673 (64.3) 0.017
6,945 (49.8) 7,535 (50.1) 0.025
ite blood cell count and triglycerides. p Values are based on 2-sample
variables.
ording to Number of NOD Risk Factors at Baseline
iglycerides 150 mg/dl, body mass index 30 kg/m2, and history of hypertension.
imva  simvastatin.ithound IDWit
in th
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group experienced 1,038 events. Among the 1,496 patients
with events, 1,207 had 1 event, 211 had 2, and 78 had 3 or
more. High-dose treatment was associated with a nonsig-
nificant reduction in the number of second and subsequent
events (HR: 0.88; 95% CI: 0.69 to 1.11; p  0.25). The
event distribution consisted of 355 CHD deaths, 1,003
nonfatal MIs, 48 resuscitated cardiac arrests, and 48 fatal
and 458 nonfatal strokes.
Discussion
The results of this analysis indicated that high-dose, com-
pared with lower-dose, statin increased the risk of NOD
among patients with 2 to 4 diabetes risk factors. No
increased risk of NOD was seen with high-dose statin
treatment in patients with 0 to 1 risk factors for diabetes.
Slightly more than half of TNT patients and nearly two-
thirds of IDEAL patients were in the low-risk group for
diabetes. Compared with low-dose statin, atorvastatin 80
mg reduced the number of CV events both in patients at
low and high risk for diabetes.
These results should reassure physicians treating patients
at low risk for diabetes. Such patients do not appear to incur
an increased risk of diabetes with high-dose atorvastatin and
derive benefit in terms of CV event reduction. Among the
6,231 patients in the TNT and IDEAL trials at high risk
for NOD, treatment with atorvastatin 80 mg compared
with a lower statin dose was associated with 80 more cases
of NOD and the prevention of 94 major CV events in 58
patients.
In the 1,501 TNT patients with established diabetes at
baseline (14), who were excluded from this analysis, the
event rate for the primary endpoint was 13.8% in the
atorvastatin 80 mg group compared with 17.9% in the 10
mg group (HR: 0.75; 95% CI: 0.58 to 0.97; p  0.026). In
the Cholesterol Treatment Trialists’ meta-analysis of
18,686 patients with diabetes in 14 randomized statin trials,
a 1-mmol/l reduction in low-density lipoprotein–
cholesterol was associated with a 21% reduction in the
number of major vascular events (15), a relative risk reduc-
tion nearly identical to that reported in all patients in statin
trials (1). In TNT patients with metabolic syndrome at
baseline (and thus at high risk for developing diabetes), the
number of primary endpoint events was 44% higher than in
TNT patients without metabolic syndrome (16), and the
primary endpoint reduction in the 80 mg compared with the
10 mg group was 29% (p  0.0001).
A patient with coronary disease who develops diabetes
aces new blood glucose monitoring requirements, increased
ietary restrictions, and usually additional chronic drug
herapy. These limitations to quality of life are accompanied
y the long-term threats of the macrovascular and micro-
ascular complications of diabetes. However, the impact of
OD is relatively minor compared with the CV eventsncluded in this analysis: CHD death, MI, resuscitatedcardiac arrest, and fatal or nonfatal stroke. Nearly 20% of
the patients (286 of 1,496) with these CV events had more
than one. Furthermore, other CV events that are prevented
by statin treatment such as coronary revascularization,
new-onset angina, and transient ischemic attack were not
included in this analysis. In considering the balance between
NOD and CV event prevention, it is worth noting that the
microvascular and macrovascular complications of diabetes
occur relatively uncommonly during the first decade after
diagnosis (17). Many patients with established vascular
disease, such as those in this study, will die from an
atherosclerotic event before they develop complications
from diabetes.
Similar findings to our study were recently reported from
the JUPITER (Justification for Use of Statins in Prevention:
an Intervention Trial Evaluating Rosuvastatin) study, in
which rosuvastatin was associated with an increased risk for
NOD in patients with, but not without, risk factors for
diabetes (18). In both groups, the number of CV events was
reduced with rosuvastatin, and benefit exceeded risk in
patients with diabetes risk factors. In a population-based
study from Taiwan, patients prescribed statins had a higher
rate of NOD during a median follow-up of 7.2 years, 2.4%
versus 2.1%, but a reduced rate of MI, stroke and in-hospital
mortality (19).
The mechanism in which statins increase the risk of
NOD has been the subject of speculation but is currently
unknown. Atorvastatin has been shown to inhibit adipose
cell maturation in cell culture and to increase insulin
resistance in type 2 diabetic mice (20). Atorvastatin and
rosuvastatin have been reported to increase insulin resistance
during coronary bypass surgery in patients without diabetes
(21). The findings of our study point to the possibility that
the mechanism may only be operative in patients with
multiple risk factors for diabetes or may be amplified under
such conditions.
Study limitations. Diabetes was not a predefined endpoint
in either the TNT or IDEAL trial, and the definition that
we adopted from Freeman et al. (12) may underestimate the
incidence of NOD because it requires 2 elevated FBG
measurements post-baseline. Glycosylated hemoglobin was
not measured routinely in either trial. Nearly all of patients
in these trials were white, and whether the results are
applicable to other populations is unknown. Some evidence
suggests that the risk of statin-associated NOD might be
higher in Japanese patients (22,23).
Conclusions
The risk of NOD did not appear to be increased with
atorvastatin 80 mg compared with moderate-dose statin
therapy during the 5-year follow-up period of the TNT and
IDEAL studies among patients with 0 to 1 of the 4 risk
factors for NOD. However, among patients with 2 to 4 risk
factors for NOD, atorvastatin 80 mg increased the risk of
NOD by 24% compared with standard therapy. In both
152 Waters et al. JACC Vol. 61, No. 2, 2013
Cardiac Risk Versus Diabetes With Atorvastatin January 15, 2013:148–52groups, high-dose therapy significantly reduced the number
of major CV events.
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